All CATEGORIES
☰ Menu


Studies show big promise for HIV prevention drug

By Marilynn Marchione
Associated Press

Print
Add This

Exciting research suggests that a shot every one to three months may someday give an alternative to the daily pills that some people take now to cut their risk of getting HIV.

The experimental drug has only been tested for prevention in monkeys, but it completely protected them from infection in two studies reported at an AIDS conference on Tuesday.

“This is the most exciting innovation in the field of HIV prevention that I’ve heard recently,” said Dr. Robert Grant, an AIDS expert at the Gladstone Institutes, a foundation affiliated with the University of California, San Francisco.

“Both groups are showing 100 percent protection” with the drug, Grant said of the two groups of researchers. “If it works and proves to be safe, it would allow for HIV to be prevented with periodic injections, perhaps every three months.”

Until a vaccine is developed, condoms are the best way to prevent infection with the AIDS virus and many other sexually spread diseases. But not everyone uses them, or does so all the time, so public health officials have pursued other prevention options.

A drug used to treat people with HIV — Gilead Science’s Truvada — also is used to help prevent infection in people who don’t have the virus. A big study in gay men a few years ago found it could cut this risk by up to 90 percent, depending on how faithfully people take the daily pills.

The new research tested something that could make this type of prevention much more practical — a long-acting experimental drug made by GlaxoSmithKline PLC. The studies tested it in macaques exposed to a human-monkey version of HIV.

Researchers at the Centers for Disease Control and Prevention gave six monkeys shots of the drug every four weeks; six others got dummy shots. All were exposed to the virus twice a week for 11 weeks.

The monkeys who got the fake treatment were readily infected “but the animals that received the long-acting drug remained protected,” said study leader Gerardo Garcia-Lerma of the CDC.

“This is really promising,” said Dr. Judith Currier, an infectious disease specialist at the University of California, Los Angeles. The research “supports moving this forward” into human testing, she said during the Conference on Retroviruses and Opportunistic Infections.


Print
Add This


MORE IN NEWS MORE IN NEWS >
EDITORS' PICKS

OHIO.COM VIDEOS

Prev Next
RealEstate
Loading...
Ohio.com Real Estate Listing Image
Norton
$154,900
Ohio.com Real Estate Listing Image
Akron
$369,900
Ohio.com Real Estate Listing Image
Hudson
$299,900
Ohio.com Real Estate Listing Image
Cuyahoga Falls
$245,000
Ohio.com Real Estate Listing Image
North Canton
$234,900
Ohio.com Real Estate Listing Image
Green
$169,900
Ohio.com Real Estate Listing Image
Akron
$695,000
Ohio.com Real Estate Listing Image
New Franklin
$159,900
Ohio.com Real Estate Listing Image
Hudson
$286,900
Ohio.com Real Estate Listing Image
Stow
$189,900
Ohio.com Real Estate Listing Image
Hudson
$249,900
Ohio.com Real Estate Listing Image
Russell Township
$365,000
Ohio.com Real Estate Listing Image
Wadsworth
$424,900
Ohio.com Real Estate Listing Image
Canton
$179,900
Ohio.com Real Estate Listing Image
Copley
$349,000
Ohio.com Real Estate Listing Image
Massillon
$179,900
Ohio.com Real Estate Listing Image
Akron
$269,900
Ohio.com Real Estate Listing Image
Hudson
$329,000
Ohio.com Real Estate Listing Image
Hudson
$475,000
Ohio.com Real Estate Listing Image
Cuyahoga Falls
$499,900

Most Read Stories